Phase II trial of AGS 16C3F in patients with renal cell carcinoma

Trial Profile

Phase II trial of AGS 16C3F in patients with renal cell carcinoma

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs AGS 16C3F (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2015 New trial record
    • 02 Jun 2015 This phase II study is planned with AGS-16C3F at 1.8 mg/kg, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top